Biological Active Reagents

Novel tyrosine kinase inhibitor for drug resistant T315I mutant BCR-ABL

Novel ERG/DNA binding inhibitor, targeting the DNA-binding activity of the human ERG transcription factor

Novel antileishmanial agent, against both intracellular Leishmania donovani and intracellular Leishmania amazonensis and displaying dose-dependent reduction of liver parasitemia

Novel protein cross-linking agent

p38 MAPK inhibitor, supressing p38 phosphorylation and LPS-induced TNF-α production in macrophages

Potent HCV NS5A inhibitor

Novel selective non-nucleoside inhibitor of DNA methyltransferase 1 (DNMT1)

Novel inhibitor of WDR5-MLL1 interaction

Novel inhibitor of menin-MLL interaction

Novel inhibitor of menin-MLL interaction

Novel inhibitor of menin-MLL interaction

Inhibitor of N-methyl transferases (NMT), preventing the formation of Parkinson's syndrome neurotoxins via methylation of non-methylated pre-neurotoxins.

Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets, significantly inhibiting leukemia cell proliferation

Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets

Novel potent CBP bromodomain inhibitor with a TR-FRET IC50 value of 19.5 ± 1.1 nM and over 400-fold of selectivity against BRD4 bromodomains

Novel potent EZH2 inhibitor

Novel potent EZH2 inhibitor

Activator of IK and SK channels

Novel inhibitor of lysine methyltransferase G9a

Highly potent agonist for group II mGlu receptors

Novel potent CDK2 inhibitor with selectivities above 10-fold over CDK1/4/6/7/9/12 above 10-fold, displaying anti-proliferative activity against A2058 melanoma and MV4-11 leukemia cell lines and low toxicity on human normal cell lines, inhibiting CDK2-medi